CRISPR Revolution: The Next Chapter in Gene Therapy
For our next in-person luncheon event, Stanford's Matthew Porteus will highlight CRISPR/Cas9's transformative impact on gene editing since its 2012 Nobel-winning discovery. This two-component system, a DNA scissor guided by RNA, led to the first CRISPR-based drug in 2023, Casgevy, for sickle cell and beta-thalassemia. Matt will explore CRISPR as a true word processor for the genome, current challenges, and the future of gene therapy.
To attend, please register here (
https://tinyurl.com/nhdw7s3x).
If you like to have lunch,
Pay $30 by June 17th at 4:00pm PST to our alumni volunteer David Adler via Venmo (
https://account.venmo.com/u/Davidladler) (last 4 digits of his phone # 7164) or Paypal (
https://www.paypal.com/paypalme/DLAInstruments).
Matthew Porteus, MD, PhD, is the Sutardja Chuk Professor of Definitive and Curative Medicine and Professor of Pediatrics at Stanford University, with appointments at the Institute for Stem Cell Biology and Regenerative Medicine and the Maternal-Child Health Research Institute. He directs the Stanford Center for Definitive and Curative Medicine and co-leads Stanford’s Cell and Gene Therapy GMP Facility. Matt was recently elected to be President of the American Society of Gene and Cell Therapy (May 2026 – May 2027).
His research centers on developing genome editing as a curative therapy, especially for hematologic disorders like sickle cell disease, as well as other organ system illnesses. Matt earned his AB in History and Science from Harvard, focusing his honors thesis on the recombinant DNA controversy of the 1970s, then completed his MD and PhD at Stanford. He was trained in Pediatric Hematology/Oncology at Boston Children’s Hospital and conducted postdoctoral research with Nobel Laureate David Baltimore at Caltech.
Clinically, Matt is an attending physician on the Pediatric Hematopoietic Stem Cell Transplant Service at Lucile Packard Children’s Hospital, treating children undergoing bone marrow transplantation for malignant and non-malignant diseases. He is committed to translating clinical practice and research into innovative, curative therapies.
Matt served on the 2017 National Academy Study Committee on Human Genome Editing and sits on the WADA Scientific Advisory Board for Cell and Gene Doping. He is a founder of CRISPR Tx, Graphite Bio, and Kamau Tx, and serves on multiple scientific advisory boards. He is a passionate advocate for developing transformative medicines in partnership with, and accessible to, global communities.
Also check out other Nonprofit events in Palo Alto, Health & Wellness events in Palo Alto.
